OpenLegislation

Division 1.1 F1

United Kingdom

Original text. Later amendments are not shown.

As a general rule, confirmation of conformity with the requirements concerning the characteristics and performances referred to in Sections 1 and 3 of Annex I, under the normal conditions of use of the device, and the evaluation of the side-effects and of the acceptability of the benefit/risk ratio referred to in Section 6 of Annex I, must be based on clinical data. The evaluation of this data, hereinafter referred to as ‘ clinical evaluation ’ , where appropriate taking account of any relevant harmonised standards, must follow a defined and methodologically sound procedure based on:

  1. 1.1.1Division 1.1.1
  2. 1.1.2Division 1.1.2
  3. 1.1.3Division 1.1.3

Annotations

Textual amendments

F1

Substituted by Directive 2007/47/EC of the European Parliament and of the Council of 5 September 2007 amending Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of biocidal products on the market (Text with EEA relevance).